Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 18, 2017
One-year data from the EWOLUTION registry found that left atrial appendage closure (LAAC) with the WATCHMAN™ device followed by dual antiplatelet therapy (DAPT) significantly reduced the risk of...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
May 17, 2016Three-months outcomes on more than 1000 patients across Europe focus on post-procedural drug regimen, impact of centre experience and peri-device leakage.
The three-month results from the EWOLUTION REgistry on WATCHMAN Outcomes in Real-Life Utilization found that LAA closure with the Boston Scientific WATCHMAN™ device has a high success rate in...
-
Nov 19, 2015First Implants Occur in Europe, Commencing Limited Market Release
Boston Scientific (NYSE: BSX) today announced that the first implants of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device – the latest generation of the WATCHMAN Device –...